






















































































































































































I- Anergic macrophage reaction 
II- Focalized histiocytic reaction 
III- Diffuse necrotizing reaction 
IV- Diffuse lympho-histiocytic reaction 




































































































































CD1a (DAKO M3571, dilution factor [df]; 1/50) 
CD68 (DAKO M0814, df; 1/100) 
CD3 (DAKO A0452, df; 1/100) 
CD8 (DAKO M-7103, df; 1/50) 
CD4 (Biosystem NCL-L-CD4368, df; 1/20) 
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The Histopathological Changes and Immunohistochemical Findings of Acute, Chronic Nonlupoid 
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Background & Aims: Dry type localized cutaneous Leishmaniasis due to Leishmania tropica is one of the 
most prevalent cutaneous parasitic infections in Kerman province. It seems that cellular immune response 
and the nature of immune inflammatory cells comprising the inflammatory background play a determinant 
role in this infection. 
Methods: Skin biopsies of 53 patients with acute(<2 years duration), nonlupoid chronic(2 years duration) 
and lupoid chronic (new lesions around old scar) types of cutaneous leishmaniasis due to Leishmania tropica 
were studied by hematoxylin-eosin staining for evaluation of inflammatory cells and epidermal and dermal 
changes. Immunohistochemical staining was used to determine immunophenotypic patterns (CD1a, CD68, 
CD3, CD8, CD4, CD20) and to evaluate host immune response at tissue level, the correlation between the 
presence and concentration of certain cell types, and the clinical presentation and duration of disease. 
Results: Mean percentages of epidermal and dermal Langerhans cells CD1a+ were higher in lupoid than in 
acute lesions. Also, the predominant T lymphocyte in acute, chronic and lupoid leishmaniasis was T CD8+. 
Conclusion: It seems that Langerhans cells CD1a+ are responsible for the suppression of the inflammatory 
response against L.tropica infection and by providing Leishmania antigens in a steady state induce tolerance 
to the Leishmania antigens and consequently cause cutaneous chronic lupoid leishmaniasis.This study also 
suggests that T CD8+ play an effective role in parasite elimination and in the process of healing of cutaneous 
leishmaniasis due to Leishmania tropica. 
Keywords:Leishmania tropica, Immunohistochemistry, CD1 antigens, CD8-positive T-Lymphocytes 
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